Tenax Therapeutics Inc (TENX)

[skyticket1]

- good enrollment update, 463 patients already 50-60 patients per month in Jan and Feb !
- trial is on track, enrollment for phase 3 completed possibly earlier than anticipated
- sufficient funds
- septic shock on the move
- 50% data read out potentially in Q2, 2016, 70% data read out potentially in Q3, 2016
- clear strategy, unmet need and good market potential

but stock under constant selling pressure ?!

It will be interesting to see after the reporting period if and which fund had to sell its position due to closure by end of Dec 2015, this is the only reasonable explanation why this stock is not much higher as of now.

to a bright future of TENX

check out the recent presentation of TENX on their web-site